Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



What the Actavis Buyout of Forest Laboratories Means for You

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Forest Laboratories (NYSE: FRX  ) , a global producer of branded pharmaceutical products, rallied as much as 37% after a deal was reached by Actavis (NYSE: AGN  ) to acquire the company for roughly $25 billion in a cash and stock deal.

So what: Under the terms of the agreement, Actavis will pay Forest Labs' shareholders $26.04 in cash per share and 0.3306 shares of Actavis common stock to acquire Forest Labs. Based on midday trading, that would value Forest Labs at roughly $94 per share, although volatility would be expected to continue in Forest shares with a good chunk of its buyout price tied to the valuation of Actavis. Actavis notes that it anticipates the deal will be immediately accretive to earnings, with double-digit accretion expected in 2015 and 2016. In addition to bringing Forest Labs' portfolio into the fold, Actavis foresees cost synergies of approximately $1 billion annually and expects free cash flow generation will top $4 billion. The deal is expected to close by mid-2014.

Now what: I am officially scratching my head here, and I believe shareholders may want to consider doing the same. Forest Labs has definitely had a number of key wins over the past year and change with antidepressant Fetzima being approved by the Food and Drug Administration, as well as irritable bowel therapy Linzess, which was co-developed with Ironwood Pharmaceuticals. However, Forest is facing the patent expiration of Alzheimer's disease drug Namenda in 2015. As of last quarter, Namenda accounted for $401.5 million of Forest's $846.8 million in total sales. In other words, Actavis just purchased a company that's set to lose half its current revenue stream next year for $25 billion!

As I've mentioned, there are positives here in that Forest is profitable and will deliver positive cash flow for Actavis, as well as long-term cost savings. Potential remains high as well for Daliresp, Tudorza, and Bystolic, which are a part of Forest's respiratory line of products. But, in the end, Actavis may have paid what I suspect could be more than eight times forward sales for a company on the edge of the patent cliff. There's plenty of opportunity for this deal to work in Actavis' favor over the long term, but I see plenty of inherent risks built into this hefty price tag.

Forest Labs may be skyrocketing today, but its gains may wind up as just peanuts next to this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2843399, ~/Articles/ArticleHandler.aspx, 9/1/2015 6:50:45 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:03 PM
AGN $294.21 Down -9.53 -3.14%
Allergen PLC CAPS Rating: ****
FRX $0.00 Down +0.00 +0.00%
Forest Laboratorie… CAPS Rating: ****